ATE219945T1 - Zusammensetzung zur verhinderung von osteolyse und metastasen - Google Patents

Zusammensetzung zur verhinderung von osteolyse und metastasen

Info

Publication number
ATE219945T1
ATE219945T1 AT96903630T AT96903630T ATE219945T1 AT E219945 T1 ATE219945 T1 AT E219945T1 AT 96903630 T AT96903630 T AT 96903630T AT 96903630 T AT96903630 T AT 96903630T AT E219945 T1 ATE219945 T1 AT E219945T1
Authority
AT
Austria
Prior art keywords
antibody
bone
pthrp
bisphosphonate
sequelae
Prior art date
Application number
AT96903630T
Other languages
English (en)
Inventor
Gregory R Mundy
Toshiyuki Yoneda
Theresa A Guise
Original Assignee
Xenotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/376,359 external-priority patent/US5626845A/en
Priority claimed from US08/386,361 external-priority patent/US5993817A/en
Application filed by Xenotech Inc filed Critical Xenotech Inc
Application granted granted Critical
Publication of ATE219945T1 publication Critical patent/ATE219945T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96903630T 1995-01-23 1996-01-23 Zusammensetzung zur verhinderung von osteolyse und metastasen ATE219945T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/376,359 US5626845A (en) 1995-01-23 1995-01-23 Method to ameliorate osteolysis and metastasis
US08/386,361 US5993817A (en) 1995-01-23 1995-02-09 Method to ameliorate osteolysis and metastasis
US48108895A 1995-06-06 1995-06-06
PCT/US1996/000895 WO1996022790A1 (en) 1995-01-23 1996-01-23 Composition to ameliorate osteolysis and metastasis

Publications (1)

Publication Number Publication Date
ATE219945T1 true ATE219945T1 (de) 2002-07-15

Family

ID=27409296

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903630T ATE219945T1 (de) 1995-01-23 1996-01-23 Zusammensetzung zur verhinderung von osteolyse und metastasen

Country Status (12)

Country Link
US (1) US20050244414A1 (de)
EP (1) EP0813423B1 (de)
JP (1) JP4231106B2 (de)
KR (1) KR100528604B1 (de)
AT (1) ATE219945T1 (de)
AU (1) AU703222B2 (de)
CA (1) CA2210484C (de)
DE (1) DE69622157T2 (de)
DK (1) DK0813423T3 (de)
ES (1) ES2179929T3 (de)
PT (1) PT813423E (de)
WO (1) WO1996022790A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914233A (en) * 1996-08-23 1999-06-22 Osteo Screen Screening assay for the identification of agents which alter expression of PTH-rP
UA75318C2 (en) * 1996-09-26 2006-04-17 Chugai Pharmaceutical Co Ltd Antibodies against protein being affined to parathyreoid human hormone
SK40599A3 (en) * 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
AU2003203622B2 (en) * 1997-05-15 2006-12-21 Chugai Seiyaku Kabushiki Kaisha Cachexia remedy
CA2289910A1 (en) 1997-05-15 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for cachexia
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
JP5232818B2 (ja) * 1998-08-06 2013-07-10 達也 沢村 酸化ｌｄｌ受容体に対する抗体を含んでなる医薬組成物
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
US20030049211A1 (en) * 2000-01-25 2003-03-13 Atsuhiko Kato Remedies and preventives for dental diseases
EP1987842A1 (de) † 2000-04-28 2008-11-05 Chugai Seiyaku Kabushiki Kaisha Zellproliferationshemmer
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
FR2841788B1 (fr) 2002-07-05 2006-01-27 Univ Pasteur Utilisation d'antagonistes de la pthrp pour traiter le carcinome a cellules renales
US20060127953A1 (en) * 2002-09-18 2006-06-15 London Health Sciences Centre Research Inc. Method of diagnosing osteolysis
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1557176A1 (de) * 2004-01-26 2005-07-27 Ferring B.V. Behandlung von Knochen-Metastasen mit Hilfe von PTH-Rezeptor-Agonisten
US9688718B2 (en) 2008-01-11 2017-06-27 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising hydrogenases and related products, methods and systems
WO2009100201A2 (en) * 2008-02-07 2009-08-13 Lawrence Livermore National Security, Llc Functionalized platform for arrays configured for optical detection of targets and related arrays, methods and systems
US9303273B2 (en) 2008-05-09 2016-04-05 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising a natural rubber biosynthetic enzyme complex and related products, methods and systems
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
US20110195862A1 (en) * 2010-02-08 2011-08-11 Pett-Ridge Jennifer Devices, methods and systems for target detection
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US20150023920A1 (en) * 2012-03-29 2015-01-22 Drexel University Novel compositions and methods for preventing or treating cancer metastasis
WO2016049061A1 (en) 2014-09-22 2016-03-31 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3267108D1 (en) * 1982-04-20 1985-12-05 Teijin Ltd Novel vitamin d3 derivatives, processes for preparation thereof, and antigens comprising said derivatives to be used for preparation of antibodies for immunochemical assay and antibodies prepared therefrom
FR2556739A1 (fr) * 1983-12-19 1985-06-21 Pasteur Institut Lignees cellulaires secretant des anticorps monoclonaux contre la pg e2, leur preparation, les anticorps obtenus et leur application
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
WO1988000596A1 (en) * 1986-07-18 1988-01-28 The University Of Melbourne A PROTEIN ACTIVE IN HUMORAL HYPERCALCEMIA OF MALIGNANCY-PTHrP
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5312810A (en) * 1987-05-20 1994-05-17 The University Of Melbourne Method and compositions for making ACSF and ACSF antagonists
DE3804686A1 (de) * 1988-02-15 1989-08-24 Henkel Kgaa Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5114843A (en) * 1988-05-09 1992-05-19 Merck & Co., Inc. Humoral hypercalcemic factor antagonists
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
EP0374510B1 (de) * 1988-12-19 1997-01-15 American Cyanamid Company Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5217896A (en) * 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0659766A1 (de) * 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
US5626845A (en) * 1995-01-23 1997-05-06 Xenotech Incorporated Method to ameliorate osteolysis and metastasis

Also Published As

Publication number Publication date
DK0813423T3 (da) 2002-07-22
CA2210484A1 (en) 1996-08-01
EP0813423B1 (de) 2002-07-03
US20050244414A1 (en) 2005-11-03
KR19980701585A (ko) 1998-05-15
AU703222B2 (en) 1999-03-18
DE69622157D1 (de) 2002-08-08
JP4231106B2 (ja) 2009-02-25
DE69622157T2 (de) 2003-03-13
KR100528604B1 (ko) 2006-03-16
WO1996022790A1 (en) 1996-08-01
EP0813423A1 (de) 1997-12-29
JPH10512885A (ja) 1998-12-08
CA2210484C (en) 2012-12-04
PT813423E (pt) 2002-11-29
AU4764596A (en) 1996-08-14
EP0813423A4 (de) 1998-04-22
ES2179929T3 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
ATE219945T1 (de) Zusammensetzung zur verhinderung von osteolyse und metastasen
EA200000718A1 (ru) Композиции целекоксиба
DE60220403D1 (de) Zusammensetzung zur unterdrückung von magensäure
KR930003912A (ko) 울혈성 심장 마비 치료법
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
GB9900334D0 (en) Tricylic vascular damaging agents
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
EA200101005A1 (ru) Высокоэффективные композиции, содержащие дигидроэрготамин
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
EP0911331A3 (de) Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
ATE393630T1 (de) Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
ATE59295T1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE69926357D1 (de) Vorbereitung eines medikaments zur behandlung von refluxösophagitis
KR900017581A (ko) α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
RU2004116067A (ru) Фармацевтические композиции, содержащие макролиды
EP0790250A3 (de) Inhibitoren des biogenen Amin Transportes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0813423

Country of ref document: EP